SCHEMBL2959285

SCHEMBL2959285

COc1cc(CC(C)NO)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 1/20 0.71
TTR P02766 1/20 0.71
JUN P05412 1/20 0.71
NR3C1 P04150 1/20 0.71
HSD17B1 P14061 1/20 0.71
HSD17B2 P37059 1/20 0.71
ALOX15 P16050 3/20 0.65
ALOX12 P18054 3/20 0.65
CYP3A4 P08684 2/20 0.62
MMP1 P03956 1/20 0.62
TAAR1 Q96RJ0 2/20 0.54
TSHR P16473 2/20 0.54
MAPK1 P28482 1/20 0.54
GAA P10253 3/20 0.53
ATM Q13315 2/20 0.53
MAPT P10636 1/20 0.53
LMNA P02545 1/20 0.53
GLA P06280 1/20 0.53
ALDH1A1 P00352 2/20 0.51
ALOX5 P09917 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3900627 0.87 FOS (0.71) FOSTTRJUNNR3C1HSD17B1
SCHEMBL3900634 0.87 FOS (0.71) FOSTTRJUNNR3C1HSD17B1
SCHEMBL2955845 0.87 LDHA (0.58) FOSTTRJUNNR3C1HSD17B1
SCHEMBL31545704 0.84 FOS (0.67) FOSTTRJUNNR3C1HSD17B1
Mesodihydroguaiaretic Acid SCHEMBL974725 0.83 FOS (1.00) FOSTTRJUNNR3C1HSD17B1
Dihydroguaiaretic Acid SCHEMBL9087980 0.83 FOS (1.00) FOSTTRJUNNR3C1HSD17B1
SCHEMBL11571527 0.83 FOS (0.80) FOSTTRJUNNR3C1HSD17B1
SCHEMBL14532804 0.81 FOS (0.77) FOSTTRJUNNR3C1HSD17B1
SCHEMBL19337385 0.81 FOS (0.77) FOSTTRJUNNR3C1HSD17B1
SCHEMBL2956883 0.81 ALOX15 (0.66) FOSTTRJUNNR3C1HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692096-B1 HYDROXYLAMINE DERIVATIVES NEWRON PHARM SPA (IT) 2013-04-03 EP claimed
US-20100197799-A1 HYDROXYLAMINE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-08-05 US claimed
US-20070049643-A1 Hydroxylamine derivatives VICURON PHARMACEUTICALS INC. 2007-03-01 US claimed
EP-1692096-A1 HYDROXYLAMINE DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2006-08-23 EP claimed
WO-2005058800-A1 HYDROXYLAMINE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-06-30 WO claimed
EP-1692096-B1 HYDROXYLAMINE DERIVATIVES NEWRON PHARM SPA (IT) 2013-04-03 EP disclosed
US-20100197799-A1 HYDROXYLAMINE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-08-05 US disclosed
US-7763751-B2 Hydroxylamine derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-07-27 US disclosed
US-20070049643-A1 Hydroxylamine derivatives VICURON PHARMACEUTICALS INC. 2007-03-01 US disclosed
EP-1692096-A1 HYDROXYLAMINE DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2006-08-23 EP disclosed
WO-2005058800-A1 HYDROXYLAMINE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197799-A1 HYDROXYLAMINE DERIVATIVES C9, C1S, HTT FOS 3493/4885TTR 94/4885JUN 4161/4885
US-20070049643-A1 Hydroxylamine derivatives C9, C1S, HTT FOS 3142/4885TTR 84/4885JUN 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.